Aspreva Pharmaceuticals has completed the enrollment of 176 patients in a Phase
III clinical study to assess the safety and efficacy of mycophenolate mofetil
(MMF or CellCept) to maintain or improve symptom control with reduced corticosteroids
in patients with myasthenia gravis.
The randomized, double-blind, placebo-controlled trial is designed to evaluate the efficacy and safety of MMF to maintain or improve symptom control with reduced corticosteroids in patients with myasthenia gravis over a treatment period of 36 weeks. The primary endpoint of responder status in the trial encompasses both minimal disease activity and low steroid dose. The company expects to complete the trial in late 2006.